ALTTO (BIG 2-06/N063D)
Clinical Trial Program
A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer.
Phase III
Status
Follow up
Tumour subtype:
HER2+
Scenario
Adjuvant
SPONSOR
PRINCIPAL INVESTIGATORS
Martine J. Piccart, MD, PhD (Jules Bordet Institute)
Edith A. Perez, MD (Mayo Clinic)
Sites
HOSPITAL CLÍNICO UNIV. LOZANO BLESA, HOSPITAL CLÍNICO UNIV. SANTIAGO DE COMPOSTELA, HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA, HOSPITAL MUTUA DE TERRASSA, HOSPITAL SON LLATZER, HOSPITAL UNIVERSITARI ARNAU DE VILANOVA DE LLEIDA, HOSPITAL UNIVERSITARI VALL D’HEBRON, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, HOSPITAL UNIVERSITARIO DR. PESET, HOSPITAL UNIVERSITARIO VIRGEN DE LA MACARENA
